24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
To ensure that patients receive optimal healthcare, clinicians rely on the best available evidence, which is often synthesized in a systematic literature review (SLR) or meta-analysis. The problem is that research never stands still, so new findings are constantly being published. This means that unless an SLR is continually updated, new findings may remain buried…
Space medicine, digital health and the patient voice were just some of the topics explored at the inaugural 2022 Australian Pharmaceutical Professionals Association (APPA) and Medical Affairs Professional Society (MAPS) joint Medical Affairs summit for the Australia and New Zealand (ANZ) region, held on 17 and 18 November in Sydney, Australia.
As part of our commitment to promoting equality, diversity and inclusivity (EDI) in the workplace and across the work that we do, Oxford PharmaGenesis is proud to sponsor the latest CISCRP educational media campaign which promotes greater patient diversity in clinical trials.
Published in late March in Cancer Informatics, our paper (Wager et al., 2022) has accumulated 11 000 views in the last 6 months. This is twice as many as the second most read article in the journal, five times that of the third most read, and 43 times the number of views that the average article…
Oxford PharmaGenesis is proud to sponsor ISMPP West 2022. On this page you can find information about our award-winning work and white papers, leaflets and more.
Thanks to colleagues who took part in the 2022 Great Place to Work survey, Oxford PharmaGenesis is ranked the UK’s no. 6 Best Workplace for Women (large company category). Executive Director Catherine Hill sits on the Oxford PharmaGenesis Board and co-leads the Regional Leadership Team for Europe. Here, she tells us about her own journey…
